We are pleased to announce that the PeerVoice activity entitled ''Advances in Adjuvant Melanoma Therapy: Working Together To Improve Outcomes’’ has now launched online. SYSF is proud to endorse this work, and applauds the valuable work put into this educational resource. This initiative features two expert...
Dr. Joel Claveau, Medical Oncologist, will review the latest news, clinical data and other updates as they relate to melanoma treatment in the adjuvant setting, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that took place in June 2018 in Chicago, Illinois and the European...
Join us for this free webinar, which reviews the latest news and clinical data related to melanoma treatment in the adjuvant setting, as presented in the 2018 conference season. 'Adjuvant' refers to patients with a stage II or stage III diagnosis. The majority of adjuvant patients typically undergo...
On September 26, 2018, you may have seen a special insert in the paper version of the National Post across the country, featuring eight pages of informative articles about immunotherapy, an innovative treatment proving successful in several cancer indications. This special content is the result...
In September 2018, Save Your Skin Foundation (SYSF) conducted an anonymous survey of melanoma patients in the adjuvant setting (diagnosed at a stage lesser than stage IV). This survey, titled "Melanoma Treatments in the Adjuvant Setting," was open globally, and we received responses from all...
Save Your Skin has the opportunity to submit patient feedback to the pCODR process for the two treatments coming to the Adjuvant setting for Melanoma patients in Canada. To learn more about the drug approval process and our involvement as a patient representation group, please...
In October I traveled to Brisbane, Australia to attend the 9th World Congress of Melanoma, a joint meeting with the Society for Melanoma Research. To be there as a melanoma patient was an incredible honour, and to be there as a representative of Save Your...
